Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$21.60
$1.00(5.99%)
At close: 4:00 PM EDT
$21.60
$1.00(5.99%)
Day’s Range― - ―
52-Week Range$16.67 - $41.51
Previous Close$18
Volume1.34M
Average Volume (3M)1.43M
Market Cap
$1.30B
Enterprise Value$1.14K
Total Cash (Recent Filing)$227.91M
Total Debt (Recent Filing)$77.50M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Oct 29, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding57,273,660
10 Day Avg. Volume934,297
30 Day Avg. Volume1,429,879
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.13Price Target Upside7.06% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$395.41M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Improving Gross MarginSustained multi-year revenue expansion combined with mid-60s gross margins indicates product-market fit and durable unit economics. High gross margin supports scalable margin expansion as procedure volumes and consumables attach rates grow, enabling operating leverage as fixed costs are spread across a larger installed base.
HYDROS Adoption & System PricingRapid new system placements and rising ASPs reflect strong commercial traction and pricing power. A growing installed base drives recurring consumables and service revenue, creating a high-margin annuity stream that supports predictable long-term revenue per system and strengthens the business model as adoption broadens.
Clinical & Regulatory SupportBroad clinical validation, peer-reviewed literature, and favorable guideline support reduce adoption friction and enhance clinician confidence. Completed pivotal trial enrollment and IDE expansion bolster long-term reimbursement and referral dynamics, underpining sustainable procedure volume growth and competitive differentiation.
Bears Say
Negative Operating & Free Cash FlowMeaningful and worsening cash burn raises financing and execution risk over the medium term. Continued negative FCF requires external capital or material margin/expense improvement; failure to stabilize cash generation could force dilution, limit commercial investment, or slow international expansion critical for durable growth.
Sizable Operating Losses & Negative MarginsPersistent large operating and net losses indicate the company has not yet achieved scale to cover a sizeable operating cost base. Until adjusted EBITDA turns sustainably positive, profitability headwinds could constrain reinvestment, pressure balance sheet equity, and leave outcomes sensitive to execution on utilization and cost controls.
Concentrated Procedure Shortfall & Upgrade DisruptionReliance on converting legacy AQUABEAM sites creates execution risk if underlying utilization underperforms. Replacement/upgrades between systems can temporarily depress procedures and consumable revenue per site. This concentration and transition friction could slow durable utilization gains and delay margin leverage.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $16.66 and its highest was $41.51 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.30B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Aug 04, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.462 by -$0.008.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.39.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 57,273,660 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.462. Following the earnings report the stock price went up 5.799%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.13 (7.06% Upside)
$23.13 (7.06% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 14.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $480.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive outlook driven by strong HYDROS adoption, record pricing, solid top-line growth (Q2 revenue +19% and procedures +21% YoY), important clinical and regulatory milestones, and a clear path to positive adjusted EBITDA in Q4 2026. Offsetting risks include a concentrated procedure shortfall in legacy AQUABEAM accounts, higher operating expenses that widened losses in the quarter, and some one-time benefits (tariff recovery) supporting margins. Management is focused on upgrades, scaling launch teams, and patient-activation initiatives to drive durable utilization improvements.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$23.13
▲(7.06% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.35% Insiders
22.34% Mutual Funds
31.71% Other Institutional Investors
25.41% Public Companies and
Individual Investors